Xtx Topco LTD Mersana Therapeutics, Inc. Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 347,255 shares of MRSN stock, worth $704,927. This represents 0.05% of its overall portfolio holdings.

Number of Shares

347,255

Previous 121,432 185.97%

Holding current value

$704,927

Previous $244,000 168.85%

% of portfolio

0.05%

Previous 0.02%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.23 - $2.25 $277,762 - $508,101	225,823 Added 185.97%	347,255 $656,000
Q2 2024 Aug 12, 2024	BUY	$2.0 - $4.45 $175,786 - $391,123	87,893 Added 262.06%	121,432 $244,000
Q1 2024 May 13, 2024	BUY	$2.16 - $5.94 $72,444 - $199,221	33,539 New	33,539 $150,000
Q3 2023 Nov 13, 2023	BUY	$1.06 - $3.91 $83,967 - $309,730	79,215 New	79,215 $100,000
Q1 2023 May 12, 2023	SELL	$4.0 - $7.02 $348,664 - $611,905	-87,166 Reduced 65.59%	45,738 $187,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $393,019 - $546,749	69,561 Added 109.82%	132,904 $778,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $113,985 - $196,952	24,619 Added 63.58%	63,343 $428,000
Q2 2022 Aug 15, 2022	BUY	$2.84 - $5.0 $81,331 - $143,190	28,638 Added 283.94%	38,724 $179,000
Q1 2022 May 13, 2022	SELL	$3.74 - $6.63 $5,811 - $10,303	-1,554 Reduced 13.35%	10,086 $40,000
Q4 2021 Feb 11, 2022	BUY	$5.48 - $9.86 $63,787 - $114,770	11,640 New	11,640 $72,000
Q3 2021 Nov 12, 2021	SELL	$8.56 - $14.47 $124,470 - $210,408	-14,541 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$13.28 - $18.07 $193,104 - $262,755	14,541 New	14,541 $197,000

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $197M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account